plozasiran sodium · Arrowhead · NDA 219947
Redemplo
Earliest generic entry, as listed
10 Sep 2038
Blocked by patent: US 10597657, US 11214801, US 12365899.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10597657 | substance, product, use U-4360 | 10 Sep 2038 |
| US 11214801 | substance, product, use U-4360 | 10 Sep 2038 |
| US 12365899 | substance, product, use U-4360 | 10 Sep 2038 |
| US 10294474 | substance, product, use U-4360 | 7 Mar 2037 |
| US 11174481 | substance, product | 7 Mar 2037 |
Exclusivities · 1 unexpired
| ODE-541 | orphan drug (7 years) | 18 Nov 2032 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219947 · 001 · RLD | solution, subcutaneous | EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) | 10 Sep 2038 |